-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UCyfikDSFT3vCgZ5dPVKsLYJR0M/CAd2i6eogO1qqX6FMhaJV0XcXVxWI67IP2HQ
 n7afLdkuPs21ea1YgBwSAg==

<SEC-DOCUMENT>0000732485-03-000040.txt : 20030807
<SEC-HEADER>0000732485-03-000040.hdr.sgml : 20030807
<ACCEPTANCE-DATETIME>20030807104449
ACCESSION NUMBER:		0000732485-03-000040
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030806
FILED AS OF DATE:		20030807

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENZYME CORP
		CENTRAL INDEX KEY:			0000732485
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				061047163
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQ
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6172527500

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			SMITH ALAN E
		CENTRAL INDEX KEY:			0001021037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14680
		FILM NUMBER:		03827930

	BUSINESS ADDRESS:	
		STREET 1:		C/O GENZYME CORP
		STREET 2:		ONE KENDALL SQ
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6172527500

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>smi71.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>
    <schemaVersion>X0201</schemaVersion>

    <documentType>4</documentType>
	<periodOfReport>2003-08-06</periodOfReport>
	<notSubjectToSection16>0</notSubjectToSection16>
    <issuer>
        <issuerCik>0000732485</issuerCik>
        <issuerName>GENZYME CORP</issuerName>
        <issuerTradingSymbol>GENZ</issuerTradingSymbol>
	</issuer>
	<reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001021037</rptOwnerCik>
            <rptOwnerName>SMITH ALAN E</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>ONE KENDALL SQUARE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02139</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
            <reportingOwnerRelationship>
			<isDirector>0</isDirector>
			<isOfficer>1</isOfficer>
			<isTenPercentOwner>0</isTenPercentOwner>
			<isOther>0</isOther>
			<officerTitle>Senior Vice President</officerTitle>
		</reportingOwnerRelationship>
	</reportingOwner>
	<nonDerivativeTable>
		<nonDerivativeTransaction>
			<securityTitle>
				<value>Genzyme General common stock (GENZ)</value>
			</securityTitle>
			<transactionDate>
				<value>2003-08-06</value>
			</transactionDate>
			<deemedExecutionDate>
				<value>2003-08-06</value>
			</deemedExecutionDate>
			<transactionCoding>
				<transactionFormType>4</transactionFormType>
				<transactionCode>M</transactionCode>
				<equitySwapInvolved>0</equitySwapInvolved>
			</transactionCoding>
			<transactionAmounts>
				<transactionShares>
					<value>15000</value>
				</transactionShares>
				<transactionPricePerShare>
					<value>7.27</value>
				</transactionPricePerShare>
				<transactionAcquiredDisposedCode>
					<value>A</value>
				</transactionAcquiredDisposedCode>
			</transactionAmounts>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>73999</value>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>D</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value/>
				</natureOfOwnership>
			</ownershipNature>
		</nonDerivativeTransaction>
		<nonDerivativeTransaction>
			<securityTitle>
				<value>Genzyme General common stock (GENZ)</value>
			</securityTitle>
			<transactionDate>
				<value>2003-08-06</value>
			</transactionDate>
			<deemedExecutionDate>
				<value>2003-08-06</value>
			</deemedExecutionDate>
			<transactionCoding>
				<transactionFormType>4</transactionFormType>
				<transactionCode>S</transactionCode>
				<equitySwapInvolved>0</equitySwapInvolved>
				<footnoteId id="F1"/>
			</transactionCoding>
			<transactionAmounts>
				<transactionShares>
					<value>15000</value>
				</transactionShares>
				<transactionPricePerShare>
					<value>44.11</value>
				</transactionPricePerShare>
				<transactionAcquiredDisposedCode>
					<value>D</value>
				</transactionAcquiredDisposedCode>
			</transactionAmounts>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>58999</value>
					<footnoteId id="F2"/>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>D</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value/>
				</natureOfOwnership>
			</ownershipNature>
		</nonDerivativeTransaction>
		<nonDerivativeHolding>
			<securityTitle>
				<value>Genzyme General common stock (GENZ)</value>
			</securityTitle>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>221</value>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>I</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value>By 401(k)</value>
				</natureOfOwnership>
			</ownershipNature>
		</nonDerivativeHolding>
	</nonDerivativeTable>
	<derivativeTable>
		<derivativeTransaction>
			<securityTitle>
				<value>Genzyme General NQ stock option (right to buy)</value>
			</securityTitle>
			<conversionOrExercisePrice>
				<value>7.27</value>
			</conversionOrExercisePrice>
			<transactionDate>
				<value>2003-08-06</value>
			</transactionDate>
			<deemedExecutionDate>
				<value>2003-08-06</value>
			</deemedExecutionDate>
			<transactionCoding>
				<transactionFormType>4</transactionFormType>
				<transactionCode>M</transactionCode>
				<equitySwapInvolved>0</equitySwapInvolved>
			</transactionCoding>
			<transactionAmounts>
				<transactionShares>
					<value>15000</value>
				</transactionShares>
				<transactionPricePerShare>
					<value>0</value>
				</transactionPricePerShare>
				<transactionAcquiredDisposedCode>
					<value>D</value>
				</transactionAcquiredDisposedCode>
			</transactionAmounts>
			<exerciseDate>
				<value>2003-06-30</value>
			</exerciseDate>
			<expirationDate>
				<value>2003-12-08</value>
			</expirationDate>
			<underlyingSecurity>
				<underlyingSecurityTitle>
					<value>Genzyme General common stock (GENZ)</value>
				</underlyingSecurityTitle>
				<underlyingSecurityShares>
					<value>15000</value>
				</underlyingSecurityShares>
			</underlyingSecurity>
			<postTransactionAmounts>
				<sharesOwnedFollowingTransaction>
					<value>10000</value>
				</sharesOwnedFollowingTransaction>
			</postTransactionAmounts>
			<ownershipNature>
				<directOrIndirectOwnership>
					<value>D</value>
				</directOrIndirectOwnership>
				<natureOfOwnership>
					<value/>
				</natureOfOwnership>
			</ownershipNature>
		</derivativeTransaction>
	</derivativeTable>
	<footnotes>
		<footnote id="F1">The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2003.</footnote>
		<footnote id="F2">The exercise of this stock option included a distribution of an additional 3 shares of Genzyme common stock.  These stock options were entitled to receive a distribution of shares of Tissue Repair common stock that was paid on July 22, 1997 to Genzyme General Division stockholders at a rate of 0.015.  In connection with the formation of Genzyme Biosurgery in December 2000, shares of Genzyme Tissue Repair were converted into shares of Genzyme Biosurgery at a rate of 0.3352.  In connection with the exchange of Genzyme Biosurgery stock into Genzyme General stock on June 30, 2003, distributions of the Genzyme Biosurgery stock are exchanged into Genzyme General stock at a rate of 0.04945.</footnote>
	</footnotes>
	<remarks>
	</remarks>
	<ownerSignature>
		<signatureName>By: Susan P. Cogswell, Attorney-in-Fact</signatureName>
		<signatureDate>2003-08-07</signatureDate>
	</ownerSignature>
	<ownerSignature>
		<signatureName>By: Susan P. Cogswell, Attorney-in-Fact</signatureName>
		<signatureDate>2003-08-07</signatureDate>
	</ownerSignature>
</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----